LOAMS
Lombard Odier Asset Management (Switzerland) Portfolio holdings
AUM
$1.98B
This Quarter Return
-6.61%
1 Year Return
+25.93%
3 Year Return
+103.45%
5 Year Return
+160.5%
10 Year Return
+469.02%
AUM
$1.27B
AUM Growth
+$1.27B
(-19%)
Cap. Flow
-$128M
Cap. Flow
% of AUM
-10.05%
Top 10 Holdings %
Top 10 Hldgs %
24.84%
Holding
415
New
40
Increased
54
Reduced
57
Closed
258
Top Buys
| 1 |
CVS Health
CVS
|
$33M |
| 2 |
Incyte
INCY
|
$26.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
$24.7M |
| 4 |
Halozyme
HALO
|
$24.5M |
| 5 |
Equity Lifestyle Properties
ELS
|
$22.9M |
Top Sells
| 1 |
Pultegroup
PHM
|
$28.6M |
| 2 |
Biogen
BIIB
|
$24.6M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$24.1M |
| 4 |
Abbott
ABT
|
$15.5M |
| 5 |
Pool Corp
POOL
|
$14.2M |
Sector Composition
| 1 | Healthcare | 56.62% |
| 2 | Financials | 13.8% |
| 3 | Consumer Discretionary | 12.01% |
| 4 | Technology | 6.24% |
| 5 | Energy | 3.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$372B
| $34.4M | 2.7% | 211,960 -25,524 | -11% | -$4.14M |
|
|
2
CVS Health
CVS
$92.8B
| $34.1M | 2.67% | 336,467 +326,473 | +3,267% | +$33M |
|
3
Thermo Fisher Scientific
TMO
$186B
| $34M | 2.67% | 57,591 -101 | -0.2% | -$59.7K |
|
|
LHCG
4
DELISTED
LHC Group LLC
LHCG
| $33.7M | 2.64% | 200,000 | – | – |
|
5
UnitedHealth
UNH
$281B
| $33.6M | 2.64% | 65,956 -15,167 | -19% | -$7.73M |
|
6
IQVIA
IQV
$32.4B
| $32.3M | 2.53% | 139,563 +6,674 | +5% | +$1.54M |
|
7
Medifast
MED
$154M
| $29.9M | 2.34% | 175,000 | – | – |
|
8
Service Corp International
SCI
$11.1B
| $29.6M | 2.32% | 450,000 | – | – |
|
|
CIXX
9
DELISTED
CI Financial Corp.
CIXX
| $27.8M | 2.18% | 1,750,000 +250,000 | +17% | +$3.97M |
|
10
Ameriprise Financial
AMP
$48.5B
| $27.3M | 2.14% | 90,978 -10,304 | -10% | -$3.09M |
|
11
Visa
V
$683B
| $27.2M | 2.14% | 122,862 +6,891 | +6% | +$1.53M |
|
12
Hologic
HOLX
$14.9B
| $26.4M | 2.07% | 343,825 +17,391 | +5% | +$1.34M |
|
|
13
Incyte
INCY
$16.5B
| $26.4M | 2.07% | +332,498 | New | +$26.4M |
|
|
14
Bristol-Myers Squibb
BMY
$96B
| $26.2M | 2.05% | 358,298 +337,756 | +1,644% | +$24.7M |
|
15
Brunswick
BC
$4.15B
| $25.1M | 1.97% | 310,037 +10,037 | +3% | +$812K |
|
16
American Express
AXP
$231B
| $25M | 1.96% | 133,557 -41,246 | -24% | -$7.71M |
|
|
17
Halozyme
HALO
$8.56B
| $24.5M | 1.92% | +614,090 | New | +$24.5M |
|
18
Labcorp
LH
$23.1B
| $23.9M | 1.88% | 90,716 -496 | -0.5% | -$131K |
|
19
GoodRx Holdings
GDRX
$1.51B
| $23.1M | 1.81% | 1,193,122 +275,849 | +30% | +$5.33M |
|
|
20
Equity Lifestyle Properties
ELS
$11.7B
| $22.9M | 1.8% | +300,000 | New | +$22.9M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.5M | 1.77% | +291,870 | New | +$22.5M |
|
22
Charles Schwab
SCHW
$174B
| $21.8M | 1.71% | 258,629 -49,943 | -16% | -$4.21M |
|
23
Tandem Diabetes Care
TNDM
$845M
| $21.7M | 1.7% | 186,756 -6,405 | -3% | -$745K |
|
24
Thor Industries
THO
$5.79B
| $21.6M | 1.7% | 275,000 +25,000 | +10% | +$1.97M |
|
25
Lowe's Companies
LOW
$145B
| $21.1M | 1.65% | 104,316 -1,236 | -1% | -$250K |
|